GlassScriptPhysician profile
Christopher P Paulson
NPI 1265428171
$6,141.36
in general payments reported to CMS, 2019-2025
27 companies · $876 in 2025
The $876 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,168 · 2020: $305 · 2021: $525 · 2022: $1,006 · 2023: $1,130 · 2024: $1,131 · 2025: $876.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,136.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $747.19 | 2019-2025 | |
| Lilly USA, LLC | $692.73 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $648.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $636.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $612.55 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $572.16 | 2019-2024 | Prolia, Evenity |
| Astellas Pharma US INC | $422.95 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $360.66 | 2019-2023 | Belsomra, Steglatro, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $199.41 | 2021-2025 | Jardiance |
| Abbott Laboratories | $159.88 | 2021-2025 | Mitraclip, Freestyle Libre 3 |
| Abbvie INC. | $137.78 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $134.76 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.42 | 2022-2025 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $98.36 | 2021-2024 | |
| Dexcom, INC. | $98.16 | 2023-2024 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $79.88 | 2019-2024 | |
| Boston Scientific Corporation | $73.92 | 2023-2024 | Watchman Flx |
| Biohaven Pharmaceutical Holding Company LTD. | $57.07 | 2022 | |
| Sumitomo Pharma America, INC. | $49.78 | 2023-2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $47.24 | 2019-2020 | |
| Genentech USA, INC. | $41.36 | 2019-2021 | |
| Amarin Pharma, INC. | $35.91 | 2019-2022 | |
| Eisai INC. | $35.07 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $33.87 | 2023 | Xarelto |
| Exact Sciences Corporation | $28.38 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $20.94 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.90 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Paulson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.